Abstract
The 4200 study is a randomized controlled trial, aimed to confirm the efficacy and safety of BIAsp 30 BID or TID in T2DM patients inadequately controlled on basal insulin, with 69% of the subjects recruited from mainland China. After 24 weeks of treatment, HbA1c level decreased comparably and hypoglycemia rates were similar between BIAsp BID and BIAsp TID groups. This study provided new evidence and inspiration for drug options in regimen adjustment for Chinese T2DM patients inadequately controlled on basal insulin.
Keywords
T2DM, BIAsp 30, Insulin regimen switch